Brainstorm Cell Therapeutics shares are trading lower after the FDA said it does not believe there is sufficient evidence to support that any of the assessed biomarkers for the company's ALS therapy is reasonably likely to predict clinical benefit.
Portfolio Pulse from Benzinga Newsdesk
The FDA has stated that it does not believe there is sufficient evidence to support that any of the assessed biomarkers for Brainstorm Cell Therapeutics' ALS therapy is reasonably likely to predict clinical benefit. This has led to a decrease in the company's share price.
September 25, 2023 | 12:21 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Brainstorm Cell Therapeutics' shares are trading lower due to the FDA's lack of belief in the evidence supporting the effectiveness of the company's ALS therapy.
The FDA's statement questioning the effectiveness of Brainstorm Cell Therapeutics' ALS therapy has led to a decrease in investor confidence, resulting in a drop in the company's share price. This is a direct impact on the company's stock price and is likely to continue in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100